explore -WSS

explore

author：explore 2025-09-29 18:15:48 - browse：4145

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Hospitals are dialing back on venture capital investing

WSS

YouTube cracks down on misinformation on cancer treatment

Illumina slashes 2023 revenue projections yet again

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

What to know about the judge who will handle the Trump case

Schizophrenia gene found to be linked to cells' energy dysfunction

Judge rejects Trump's counterclaim against E. Jean Carroll

focus

explore

entertainment

Sports medicine is finally prioritizing gender equality

FTX founder Sam Bankman

How one medical school became remarkably diverse

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Schizophrenia gene found to be linked to cells' energy dysfunction

After affirmative action ruling, medical educators look to 'holistic review'

Hospitals use virtual reality to design more inclusive rooms for kids

Walensky prepares to leave CDC — and Congress — behind

Dozens dead from Maui wildfires: What we know about the victims

knowledge

‘The Bear’ and hospitality in hospitals

Dozens dead from Maui wildfires: What we know about the victims

Zapping the brain for stroke rehab: Pivotal clinical trial begins

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Timeline: How the deadly wildfires took over Maui day by day

Illumina slashes 2023 revenue projections yet again

knowledge

focus

hotspot

focus